Anti-CMV Pilot Clinical Trial: Prophylaxis of Cytomegalovirus Infection in Haploidentical Transplatation of Hematopoietic Progenitors With Adoptive Cell Inmunotherapy
Overview
- Phase
- Phase 2
- Status
- Recruiting
- Sponsor
- Instituto de Investigación Marqués de Valdecilla
- Enrollment
- 15
- Locations
- 1
- Primary Endpoint
- 100-days incidence of CMV infection
Overview
Brief Summary
Cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). Recently, strategies based on immunotherapy adoptive cells (IAC) with anti-CMV Cytolitic T Lymphocytes (CMV-CTLs) has been incorporated to prevent or treat CMV after HSCT. The aim to study donor derived CMV-CTLs after haploidentical HSCT (HAPLO) as prophylaxis for CMV infection in transplant patients. CMV-CTLs will be administer at day 21 (+-7 days) post-HAPLO. CMV DNA levels with quantitative PCR will be weekly monitored.
Detailed Description
In HAPLO, CMV infection and disease are more frequent than in other type of HSCT, this is related to delayed immune reconstitution after transplant increasing post-transplant infectious complications. Approximately 60% of patients reactivated CMV infection after HAPLO and 15%, developed CMV disease afecting organs and causing the death of the patient in 8% of CMV disease cases.
If patient and donor are eligible, it will take 1x10^9 cells from donor leukapheresis. Donor cells will be selected and procesed by CliniMACs PRODIGY and after 12h it will obtain 7mL of CMV-CTLs. It will use 6mL of CMV-CTLs to infused a dose of 1x10^5 cells/kg in our patient. The donor derived CMV-CTL cells will be transfused into the patients' intravenous line. The patients will receive the dose of CMV-CTL cells when they are sero-positive for CMV-DNA 21 (+- 7 days) days after transplant.
The CMV-DNA levels will be monitored weekly for at least 100 days after the transplant. If after the initial dose of CMV-CTL cells the patient develops a viral infection, then the patient will receive treatment with anti-CMV comercial drugs.
Study Design
- Study Type
- Interventional
- Allocation
- Na
- Intervention Model
- Single Group
- Primary Purpose
- Prevention
- Masking
- None
Eligibility Criteria
- Ages
- 18 Years to 80 Years (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •Adult patients who received an alogeneic stem cell transplantation from haploidentical donors (HAPLO).
- •Any source of stem cells (peripheral blood or bone marrow).
- •CMV-seropositive donors.
- •Negative pregnancy test in women.
- •Signed writen informed consent.
- •HLA haploidentical and CMV-seropositve donors.
- •Donor must be checked and suitable.
- •Signed writen informed consent.
- •Donor without active infection evidence at leukapheresis.
Exclusion Criteria
- •Patients without haploidentical CMV-seropositive donors.
- •Patients who are not suitable for follow up visits.
- •CMV-CTLs Infusion Criteria:
- •Hematopoiesis recovery at least partial (neutrophil counts \>0.5x10\^9/L in at least 3 consecutive samples post-transplant).
- •CMV-CTLs NON-Infusion Criteria:
- •Patients receiving corticosteroid (dose of 0.5mg/kg/day of prednisone or equivalent) at infusion.
- •ECOG \> or =
- •Organic toxicities grade \> or =
- •Patients who received ATG, donor lymphocytes or alemtuzuamb, 28 days pre-infusion.
- •Patients with uncontroled infection defined by fevers and/or inestability and/or infection not resolved.
Outcomes
Primary Outcomes
100-days incidence of CMV infection
Time Frame: From date of CMV-CTLs infusion to 100 days after transplant
Viral load \>200 copies in 1 sample
Secondary Outcomes
- 1-year incidence of CMV specific antiviral drug use(From date of CMV-CTLs infusion to 1 year after transplant)
- 1-year incidence of CMV disease(From date of CMV-CTLs infusion to 1 year after transplant)